Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Garcia-Manero, Guillermo
Scott, Bart L.
Kishtagari, Ashwin
Sanikommu, Srinivasa R.
Al-Kali, Aref
Lee, Je-Hwan
Burgues, Juan M. Bergua
Diez-Campelo, Maria
Erba, Harry P.
Garcia-Hernandez, Carmen
Santillana, Guillermo Sanz
O'Connell, Casey
Jang, Jun-Ho
Shin, Dong-Yeop
Sayar, Hamid
Rao, Mayank
Schwartz, Richard S.
An, Grace
Jin, Feng
Forgie, Alison J.
Tsiatis, Athanasios C.
Altman, Jessica K.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT060
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [12] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [13] The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan
    Hong, Wen-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Dunbar, Martin
    Harb, Jason G.
    Popovic, Relja
    Tanwani, Poonam
    Gopalakrishnan, Sathej
    Wolff, Johannes
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S316
  • [14] Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
    Sallman, David
    Al Malki, Monzr
    Asch, Adam
    Wang, Eunice
    Jurcic, Joseph
    Bradley, Terrence
    Flinn, Ian
    Pollyea, Daniel
    Kambhampati, Suman
    Tanaka, Tiffany
    Zeidner, Joshua
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Lal, Indu
    Vyas, Paresh
    Daver, Naval
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S314 - S315
  • [15] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [16] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    Leukemia, 2016, 30 : 1795 - 1796
  • [17] A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
    Wei, Andrew H.
    Garcia, Jacqueline S.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph G.
    Garcia-Manero, Guillermo
    Hong, Wan-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Dunbar, Martin
    Zhou, Ying
    Harb, Jason
    Tanwani, Poonam
    Wolff, Johannes E.
    Jacoby, Meagan
    BLOOD, 2019, 134
  • [18] Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Bouchla, Anthi
    Thomopoulos, Thomas P.
    Papageorgiou, Sotirios G.
    Apostolopoulou, Christina
    Loucari, Constantinos
    Mpazani, Efthimia
    Pappa, Vasiliki
    EPIGENOMICS, 2021, 13 (14) : 1129 - 1143
  • [19] WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Falconi, Giulia
    Fabiani, Emiliano
    Ottone, Tiziana
    Piciocchi, Alfonso
    Lavorgna, Serena
    Criscuolo, Marianna
    Fianchi, Luana
    Gurnari, Carmelo
    Postorino, Massimiliano
    Picardi, Alessandra
    Palmieri, Raffaele
    Lo-Coco, Francesco
    Voso, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 979 - 982
  • [20] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
12345